Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052908 · ClinicalTrials.gov registry record · Phase 1
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT02052908: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02052908 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02052908, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This randomized phase Ib trial studies the side effects and best dose of naproxen in preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of naproxen may keep cancer from forming in patients with Lynch syndrome.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Naproxen
- OTHER Placebo Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2014-01-27 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052908
The ClinicalTrials.gov registry entry for NCT02052908 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02052908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052908 about?
NCT02052908 is a clinical study titled "Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome". This randomized phase Ib trial studies the side effects and best dose of naproxen in preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of naproxen may ke...
What is the current status of trial NCT02052908?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2014-01-27. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT02052908?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Naproxen (DRUG), Placebo Administration (OTHER).
Who is sponsoring clinical trial NCT02052908?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.